The Product Ignition & Development Enabler (mPRiDE) programme of the Indian Council of Medical Research (ICMR) has shortlisted three companies: Udyog Yantra Technologies Pvt Ltd, LVP Eye Innovations, Hyderabad, and Evelabs Technologies Pvt Ltd, Kollam. The programme aims to accelerate…
Embarking on a career in pharmacy in Uttar Pradesh? Congratulations on taking the first step toward professional recognition! To ensure a seamless journey into the vibrant world of pharmaceuticals, understanding the process of obtaining new registration with the Uttar Pradesh Pharmacy Council is crucial.
A. Criteria of Minimum Qualification :-Candidate should Be :-1. D. Pharm (Diploma In Pharmacy)2. B. Pharm (Bachelor of Pharmacy)3. Pharm.D / Pharm.D (Post Baccalaureate)Above degree should be from the colleges having recognition from Pharmacy Council Of India. B. Training Certificate…
1. General Instructionsa. The applicant should be a Citizen of India and should have completed 18 years of age.b. Registerable Qualifications – D. Pharm, B. Pharm, Pharm D approved by Pharmacy Council of Indiac. Institution / College should have been…
The Kyasanur Forest Disease Vaccine (KFDV) isolate will be used in R&D activities by experienced vaccine manufacturers, pharmaceutical corporations, and research and development organisations for the development of a vaccine against KFD and its manufacture or commercialization. In order to…
Altuviiio [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa, is a first-in-class, highly sustained factor VIII replacement therapy that has received FDA approval. For both adults and children with haemophilia A, the use of altuviiio is recommended…
M1 MedDRA Terminology M1: MedDRA- Medical Dictionary for Regulatory Activities M1: PtC WG MedDRA Points to Consider M2 Electronic Standards M2: EWG Electronic Standards for the Transfer of Regulatory Information M3 Nonclinical Safety Studies M3(R2): Guidance on Nonclinical Safety Studies…
Model Paper-1 Model Paper-2 Model Paper-3 Model Paper-4 Model Paper-5
E1: Clinical Safety for Drugs used in Long Term Treatment E1: The Extent Of Population Exposure To Assess Clinical Safety for Drugs intended for long term treatment of non-life threatening conditions. E2A-E2F: Pharmacovigilance E2A: Clinical Safety Data Management: Definitions and…
In order to identify potential dangers including carcinogenicity, genotoxicity, and reprotoxicity, ICH has created a thorough set of safety guidelines. A non-clinical testing approach for determining the QT interval prolongation liability—the leading factor in drug withdrawals in recent years—has made…
This will close in 0 seconds
